Table 2 Treatment-related adverse events

From: Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)

 

AA + Prednisone

AA + Dexamethasone

 

Grade 1

Grade 2

Grade 3/4

Grade 1

Grade 2

Grade 3/4

Hypertension

1

2

0

1

1

0

Hypokalaemia

2

0

0

0

0

0

Oedaema

1

0

0

0

0

0

Hyperglycaemia

1

0

0

1

1

0

Hypertransaminasemia

1

0

0

0

0

0

Hypotension

0

0

0

1

0

0

Muscle weakness

0

0

0

3

0

0

Total events

6

2

0

6

2

0

Back to article page